Premila D Leiphrakpam1, Audrey J Lazenby2, Lynette M Smith3, Michael G Brattain4, Jennifer D Black4, Jing Wang5, Chandrakanth Are6. 1. Department of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. 2. Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. 3. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA. 4. Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA. 5. Department of Cancer Biology and Genetics, College of Medicine, Ohio State University, Columbus, Ohio, USA. 6. Division of Surgical Oncology, Department of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Abstract
OBJECTIVES: To evaluate the relationship between phosphatase of regenerating liver 3 (PRL3) expression and clinical outcome in colorectal cancer (CRC). BACKGROUND: PRL3, a protein tyrosine phosphatase functions as one of the key regulatory enzymes of various signal transduction pathways. PRL3 is highly expressed in a majority of cancers and is a novel potential therapeutic target. METHODS: PRL3 expression was evaluated by immunohistochemistry in 167 patients with CRC, 37 patients with no disease, and 26 patients with metastatic CRC (mCRC). Phosphorylated Akt at serine 473 (p-Akt S473) expression was also evaluated by immunohistochemistry in mCRC patients. RESULTS: High expression of PRL3 was correlated with CRC progression, and every one unit increase in PRL3 level contributed to an increase in the rate of death by 1%-1.7%. PRL3 expression was significantly higher in liver metastases compared with primary tumors and showed a significant positive correlation with the expression level of p-Akt S473. CONCLUSION: PRL3 expression levels associated with CRC progression and metastasis, and positively correlated with activated Akt level in mCRC. Together, these findings indicated that PRL3 might be a potential marker for increased risk of CRC-specific tumor burden and identify PRL3 as an attractive therapeutic target for mCRC treatment.
OBJECTIVES: To evaluate the relationship between phosphatase of regenerating liver 3 (PRL3) expression and clinical outcome in colorectal cancer (CRC). BACKGROUND: PRL3, a protein tyrosine phosphatase functions as one of the key regulatory enzymes of various signal transduction pathways. PRL3 is highly expressed in a majority of cancers and is a novel potential therapeutic target. METHODS: PRL3 expression was evaluated by immunohistochemistry in 167 patients with CRC, 37 patients with no disease, and 26 patients with metastatic CRC (mCRC). Phosphorylated Akt at serine 473 (p-Akt S473) expression was also evaluated by immunohistochemistry in mCRC patients. RESULTS: High expression of PRL3 was correlated with CRC progression, and every one unit increase in PRL3 level contributed to an increase in the rate of death by 1%-1.7%. PRL3 expression was significantly higher in liver metastases compared with primary tumors and showed a significant positive correlation with the expression level of p-Akt S473. CONCLUSION: PRL3 expression levels associated with CRC progression and metastasis, and positively correlated with activated Akt level in mCRC. Together, these findings indicated that PRL3 might be a potential marker for increased risk of CRC-specific tumor burden and identify PRL3 as an attractive therapeutic target for mCRC treatment.
Authors: Rui Wang; Rajat Bhattacharya; Xiangcang Ye; Fan Fan; Delphine R Boulbes; Lee M Ellis Journal: Mol Cancer Res Date: 2018-08-21 Impact factor: 5.852
Authors: U A Miskad; S Semba; H Kato; Y Matsukawa; Y Kodama; E Mizuuchi; N Maeda; K Yanagihara; H Yokozaki Journal: Virchows Arch Date: 2007-01-18 Impact factor: 4.064
Authors: Premila D Leiphrakpam; Audrey J Lazenby; Sanjib Chowdhury; Lynette M Smith; Michelle Mathiesen; Michael G Brattain; Jing Wang; Jennifer D Black; Chandrakanth Are Journal: J Surg Oncol Date: 2019-12-22 Impact factor: 3.454